Skip to main content
SpringerLink
Log in

A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas

  • Letter to the Editor
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361(4):358–67

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Giovannini M, Bonne NX, Vitte J, Chareyre F, Tanaka K, Adams R, Fisher LM, Valeyrie-Allanore L, Wolkenstein P, Goutagny S, Kalamarides M (2014) mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro Oncol 16(4):493–504

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Goutagny S, Raymond E, Esposito-Farese M, Trunet S, Mawrin C, Bernardeschi D, Larroque B, Sterkers O, Giovannini M, Kalamarides M (2015) Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol 122(2):313–320

    Article  CAS  PubMed  Google Scholar 

  4. Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, Barker FG, Connor S, Evans DG, Fisher MJ, Goutagny S, Harris GJ, Jaramillo D, Karajannis MA, Korf BR, Mautner V, Plotkin SR, Poussaint TY, Robertson K, Shih CS, Widemann BC, REiNS International Collaboration (2013) Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 81:S33–S40

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, 100 boulevard du General Leclerc, 92100, Clichy, France

    Stéphane Goutagny

  2. Neurochirurgie, Hôpital Pitié Salpêtrière, Assistance Publique Hôpitaux de Paris, 47-83, boulevard de l’Hôpital, 75013, Paris, France

    Michel Kalamarides

  3. University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA, 90095-1624, USA

    Marco Giovannini

Authors
  1. Stéphane Goutagny
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Giovannini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michel Kalamarides
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michel Kalamarides.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goutagny, S., Giovannini, M. & Kalamarides, M. A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas. J Neurooncol 133, 443–445 (2017). https://doi.org/10.1007/s11060-017-2447-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-017-2447-3

Keywords

Search

Navigation